Valuation: Keros Therapeutics, Inc.

Market Cap 210M 182M 171M 155M 292M 20.16B 297M 2.01B 786M 10.08B 790M 773M 33.58B P/E 2026 *
-1.95x
P/E 2027 * -1.69x
Enterprise Value 210M 182M 171M 155M 292M 20.16B 297M 2.01B 786M 10.08B 790M 773M 33.58B EV / Sales 2026 *
12.8x
EV / Sales 2027 * 16.6x
Free-Float
46.47%
Yield 2026 *
-
Yield 2027 * -
1 day+1.51%
1 week-0.28%
Current month+5.36%
1 month-0.28%
3 months+4.43%
6 months-34.38%
Current year-47.89%
1 week 10
Extreme 10
11.43
1 month 9.69
Extreme 9.69
11.43
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 01/12/2015
Director of Finance/CFO 55 03/08/2026
Chief Tech/Sci/R&D Officer 53 01/06/2019
Director TitleAgeSince
Chairman 70 01/07/2024
Director/Board Member 63 01/04/2016
Director/Board Member 50 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
4/8/26 Other

Chief Financial Officer

117,468 0.5935%
15/7/26 Buy

Chairman

1,000 0.0051%
1/7/26 Free

Director

28,656 0.1448%
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%-0.28%-26.93%-68.98% 210M
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.76%+14.90%+56.42%+91.71% 62.99B
+0.60%-3.10%+0.94%+491.16% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+16.72%-0.05%-17.59%-15.96% 23.3B
+1.64%+4.47%+40.42%-14.71% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+0.07%+3.49%+40.68%+151.75% 13.16B
Average +1.49%+2.88%+48.60%+171.00% 28.07B
Weighted average by Cap. +1.28%+5.47%+57.09%+164.10%

Financials

2026 *2027 *
Net sales 16.37M 14.14M 13.3M 12.09M 22.74M 1.57B 23.07M 156M 61.16M 785M 61.46M 60.13M 2.61B 12.64M 10.91M 10.27M 9.33M 17.55M 1.21B 17.81M 120M 47.2M 605M 47.44M 46.41M 2.02B
Net income -108M -93.66M -88.12M -80.09M -151M -10.39B -153M -1.03B -405M -5.2B -407M -398M -17.31B -147M -127M -120M -109M -204M -14.09B -207M -1.4B -550M -7.05B -552M -540M -23.48B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
19/08/26 USD 10.61 +1.24% 256,149
17/08/26 USD 10.48 +3.76% 221,513
14/08/26 USD 10.10 -5.25% 315,284
13/08/26 USD 10.66 -4.82% 239,468
12/08/26 USD 11.20 +5.26% 159,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
10.61USD
Average target price
19.83USD
Spread / Average Target
+86.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock